Evidence map›Paper›PMID 32376238›Full record

ReviewChemico-biological interactions2020

Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective.

Parteek Prasher, Mousmee Sharma, Meenu Mehta, Keshav R Paudel, Saurabh Satija, Dinesh K Chellappan, Harish Dureja, Gaurav Gupta, Murtaza M Tambuwala, Poonam Negi and 4 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemico-biological interactions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
10.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Phytochemical Elucidation and Effect ofPlants (Basel, Switzerland) · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 4 countries.

Parteek PrasherDepartment of Chemistry, University of Petroleum & Energy Studies, Dehradun, 248007, India.
Mousmee SharmaDepartment of Chemistry, Uttaranchal University, Dehradun, 248007, India.
Meenu MehtaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia.
Keshav R PaudelCentre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Saurabh SatijaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, Punjab, India.
Dinesh K ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
Harish DurejaDepartment of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, Haryana, 124001, India.
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India.
Murtaza M TambuwalaSchool of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, County Londonderry, BT52 1SA, Northern Ireland, United Kingdom.
Poonam NegiSchool of Pharmaceutical Sciences, Shoolini University, Bajhol, Sultanpur, Solan, Himachal Pradesh, 173229, India.
Peter R WichAustralian Centre for NanoMedicine, University of New South Wales, Sydney, NSW, 2052, Australia; School of Chemical Engineering, University of New South Wales, Sydney, NSW, 2052, Australia.
Nicole G HansbroCentre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia.
Philip M HansbroCentre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050, Australia; School of Pharmaceutical Sciences, Shoolini University, Bajhol, Sultanpur, Solan, Himachal Pradesh, 173229, India; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia. Electronic address: Kamal.Dua@uts.edu.au.
University of Technology Sydney · AUCentenary Institute · AUGyan Vihar University · INInternational Medical University · MYMaharshi Dayanand University · INShoolini University · INUniversity of Petroleum and Energy Studies · INUniversity of Ulster · GBUNSW Sydney · AUUttaranchal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The apparent predicament of the representative chemotherapy for managing respiratory distress calls for an obligatory deliberation for identifying the pharmaceuticals that effectively counter the contemporary intricacies associated with target disease. Multiple, complex regulatory pathways manifest chronic pulmonary disorders, which require chemotherapeutics that produce composite inhibitory effect. The cost effective natural product based molecules hold a high fervor to meet the prospects posed by current respiratory-distress therapy by sparing the tedious drug design and development archetypes, present a robust standing for the possible replacement of the fading practice of poly-pharmacology, and ensure the subversion of a potential disease relapse. This study summarizes the experimental evidences on natural products moieties and their components that illustrates therapeutic efficacy on respiratory disorders.

Indexed as

AnimalsChronic DiseaseHumansMolecular Targeted TherapyPlant ExtractsRespiratory Tract DiseasesPlant ExtractsAlkaloidsCOPDFlavonoidsNatural productsRespiratory disorders

Identifiers

PMID32376238
PMCPMC7196551
OpenAlexW3023385072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.